ASCO GUIDELINES Bundle

Estrogen and Progesterone Receptor Testing in Breast Cancer

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1199868

Contents of this Issue

Navigation

Page 5 of 13

6 Diagnosis Table 1. Invasive Breast Cancer Histopathologic Concordance with Estrogen Receptor Staining HIGHLY UNUSUAL ER NEGATIVE RESULTS HIGHLY UNUSUAL ER POSITIVE RESULTS • Low grade invasive carcinomas of no special type (also known as invasive ductal carcinoma) • Metaplastic carcinomas of all subtypes • Lobular carcinomas (classic type) • Adenoid cystic carcinomas and other salivary gland-like carcinomas of the breast • Pure tubular, cribriform, or mucinous carcinomas • Secretory carcinoma • Encapsulated papillary and solid papillary carcinomas • Carcinomas with apocrine differentiation Note: If a result is considered highly unusual/discordant, additional steps should be taken to check the accuracy of the histologic type or grade as well as the pre-analytic and analytic testing factors. is work-up may include second reviews and repeat testing. If all results appear valid the result can be reported with a comment noting that the findings are highly unusual and testing of additional samples may be of value to confirm the findings.

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Estrogen and Progesterone Receptor Testing in Breast Cancer